

REMARKS/ARGUMENTS

Claims 1-10 and 17-26 are pending. Claims 1-10 are currently amended and discussed below. Claims 11-16 are canceled without prejudice. Claims 17-26 are added. Claim 17 finds support in original claim 11. Claim 18 finds support in original claim 10. Claims 19 and 20 find support in original claim 12. Claims 21 and 22 find support in original claim 13. Claims 23 and 24 find support in original claim 14. Claim 25 finds support in original claim 15. Claim 26 finds support in original claim 16. No new matter has been entered.

35 U.S.C. §112 (1st paragraph)

The rejection of claims 1-16 for lack of enablement of prevention of certain diseases has been obviated by the removal of prevention from the claims. However, it is noted that the Office has asserted that the specification is “enabling for *treating* certain disease states” (Office Action, page 2, para. 3). Thus, treatment has not been removed from the claims.

35 U.S.C. §112 (2nd paragraph)

A) The rejection of claims 1-4 for incorrectly naming the compound has been obviated by the amendment of “heterocycle” to “aromatic heterocycle”. Since “aryl” includes any aromatic compound, including aromatic heterocycles, the compound is now correctly named.

B) The rejection of claims 1-8 and 10-16 for improper recitation of the term “derivatives” has been obviated by the amendment of “derivatives” to “compound”.

C) The rejection of claims 1-9 for improper recitation of the term “general formula” has been obviated by the amendment of “general formula” to “formula”.

D) The rejection of claims 1-8 and 10-16 for improper recitation of the term “and ... salts” has been obviated by the amendment of “and their pharmacologically acceptable addition salts” to “or a pharmacologically acceptable addition salt thereof”.

E) The rejection of claim 9 for improper recitation of the term “Compounds” has been obviated by the amendment of “Compounds” to “The compound”.

F) The rejection of claims 10-16 for being identical to claims 1-9 has been obviated by the current amendments as follows. Claims 1-8 are the compound of claim 1 or a pharmacologically acceptable addition salt thereof, and claim 9 is a Markush group of specifically enumerated compounds of claim 1. However, claim 10 is an inhibitor comprising at least one compound of claim 1, claim 17 (from claim 11) is a pharmaceutical composition, and claims 18-26 are methods of treatment comprising administering the compound of claim 1. Therefore claims 10 and 17-26 are not identical to claims 1-9.

G) The rejection of claims 10-16 for being unclear as to whether a pharmaceutical composition is being claimed has been obviated by the current amendments as discussed above in part F).


Information Disclosure Statement

It is respectfully requested that the Examiner consider and initial reference AA on Form PTO 1449 submitted January 19, 2005.

Accordingly, and in view of the Office’s assertion that the “references alone or in combination do not teach nor suggest structurally similar compounds as those instantly claimed” (Office Action, page 3, para. 6), Applicants submit that all now-pending claims are in condition for allowance. Applicants respectfully request the withdrawal of the rejections and passage of this case to issue.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Justine M. Wilbur
Attorney of Record
Registration No. 59,678

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)